Ignite Creation Date:
2025-12-25 @ 2:07 AM
Ignite Modification Date:
2025-12-27 @ 11:48 PM
Study NCT ID:
NCT00425360
Status:
COMPLETED
Last Update Posted:
2013-08-26
First Post:
2007-01-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010190', 'term': 'Pancreatic Neoplasms'}], 'ancestors': [{'id': 'D004067', 'term': 'Digestive System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D004701', 'term': 'Endocrine Gland Neoplasms'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D010182', 'term': 'Pancreatic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C081222', 'term': 'sargramostim'}, {'id': 'D000069287', 'term': 'Capecitabine'}, {'id': 'D000093542', 'term': 'Gemcitabine'}], 'ancestors': [{'id': 'D003841', 'term': 'Deoxycytidine'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D005472', 'term': 'Fluorouracil'}, {'id': 'D014498', 'term': 'Uracil'}, {'id': 'D011744', 'term': 'Pyrimidinones'}, {'id': 'D003853', 'term': 'Deoxyribonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 1110}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2006-09'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2009-05', 'completionDateStruct': {'date': '2013-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2013-08-23', 'studyFirstSubmitDate': '2007-01-19', 'studyFirstSubmitQcDate': '2007-01-19', 'lastUpdatePostDateStruct': {'date': '2013-08-26', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2007-01-23', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Survival at 1 year'}], 'secondaryOutcomes': [{'measure': 'Time to progression'}, {'measure': 'Quality of life as assessed by the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life (QLQ) C30 questionnaire and the European Study group for Pancreatic Cancer-QLQ questionnaire'}, {'measure': 'Clinical benefit response'}, {'measure': 'Objective response rate as assessed by RECIST criteria'}, {'measure': 'Toxicity as assessed by NCI CTCAE version 3'}, {'measure': 'Survival and response as assessed by delayed-type hypersensitivity'}]}, 'conditionsModule': {'keywords': ['stage III pancreatic cancer', 'stage IV pancreatic cancer', 'duct cell adenocarcinoma of the pancreas', 'recurrent pancreatic cancer'], 'conditions': ['Pancreatic Cancer']}, 'descriptionModule': {'briefSummary': 'RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving more than one drug (combination chemotherapy) together with vaccine therapy may kill more tumor cells. It is not yet known whether chemotherapy is more effective with or without vaccine therapy in treating pancreatic cancer.\n\nPURPOSE: This randomized phase III trial is studying gemcitabine, capecitabine, and vaccine therapy to see how well they work compared with gemcitabine and capecitabine alone in treating patients with locally advanced or metastatic pancreatic cancer.', 'detailedDescription': 'OBJECTIVES:\n\nPrimary\n\n* Determine the efficacy of telomerase peptide vaccine GV1001 when administered concurrently or sequentially with gemcitabine hydrochloride and capecitabine, in terms of survival, in patients with locally advanced or metastatic pancreatic cancer.\n\nSecondary\n\n* Determine the safety of this regimen in these patients.\n* Assess the immunogenicity of this regimen in these patients.\n* Determine the time to progression in patients treated with this regimen.\n* Determine the quality of life of patients treated with this regimen.\n* Determine the clinical benefit response in patients treated with this regimen.\n* Determine the objective response rate in patients treated with this regimen.\n* Determine the toxicity of this regimen in these patients.\n* Determine the survival and response by delayed-type hypersensitivity in patients treated with this regimen.\n\nOUTLINE: This is a prospective, controlled, randomized, open-label, multicenter study. Patients are stratified according to stage of disease (locally advanced vs metastatic) and ECOG performance status (0 vs 1 vs 2). Patients are randomized to 1 of 3 treatment arms.\n\n* Arm I: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 1-21. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.\n* Arm II: Patients receive gemcitabine hydrochloride and capecitabine as in arm I. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive sargramostim (GM-CSF) intradermally (ID) and telomerase peptide vaccine GV1001 ID on days 1, 3, and 5 in week 9, once a week in weeks 10-12 and 14, and then once a month in the absence of disease progression or unacceptable toxicity. Patients who develop disease progression while on vaccine therapy, discontinue vaccine therapy and then restart treatment with gemcitabine hydrochloride and capecitabine. Patients receive gemcitabine hydrochloride and capecitabine as above and continue treatment in the absence of further disease progression or unacceptable toxicity.\n* Arm III: Patients receive gemcitabine hydrochloride and capecitabine as in arm I. Patients also receive GM-CSF ID and telomerase peptide vaccine GV1001 ID on days 1, 3, and 5 in week 1, once weekly in weeks 2, 3, 4 and 6, and then once a month in the absence of disease progression or unacceptable toxicity.\n\nQuality of life is assessed at baseline and at 8 weeks and then every 12 weeks during study treatment.\n\nAfter completion of study treatment, patients are followed every 3 months.\n\nPeer Reviewed and Funded or Endorsed by Cancer Research UK\n\nPROJECTED ACCRUAL: A total of 1,110 patients will be accrued for this study.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas\n\n * Locally advanced or metastatic disease precluding curative surgical resection\n* Unidimensionally measurable disease by CT scan\n* No intracerebral metastases or meningeal carcinomatosis\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* Life expectancy \\> 3 months\n* WBC \\> 3,000/mm³\n* Absolute neutrophil count \\> 1,500/mm³\n* Platelet count \\> 100,000/mm³\n* Bilirubin \\< 2.0 mg/dL\n* Creatinine clearance \\> 50 mL/min\n* No medical or psychiatric condition that would preclude giving informed consent\n* No clinically significant serious disease or organ system disease not currently controlled on present therapy\n* No uncontrolled angina pectoris\n* Not pregnant or nursing\n* Fertile patients must use a condom and ≥ 1 other form of contraception during and for 1 year after completion of study treatment\n* No other malignancies or invasive cancers within the past 5 years except for adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix\n* No known malabsorption syndrome\n* No known hypersensitivity to any of the investigational agents\n* No dihydropyrimidine dehydrogenase deficiency\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior chemotherapy\n* No radiotherapy within the past 4 weeks\n* No concurrent medications that could affect immunocompetence (e.g., chronic treatment with long-term steroids or other immunosuppressants for unrelated condition)\n\n * Concurrent short-term steroids for palliation of cancer-related symptoms allowed\n* No other concurrent investigational drugs or cytotoxic agents\n* No other concurrent immunotherapy (e.g., immunosuppressants or chronic use of systemic corticosteroids) or chemotherapy for another tumor in patients receiving telomerase peptide vaccine GV1001\n\n * Concurrent low-dose corticosteroids may be allowed'}, 'identificationModule': {'nctId': 'NCT00425360', 'briefTitle': 'Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer', 'organization': {'class': 'NIH', 'fullName': 'National Cancer Institute (NCI)'}, 'officialTitle': 'A Prospective, Phase III, Controlled, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Capecitabine Therapy With Concurrent and Sequential Chemoimmunotherapy Using a Telomerase Vaccine in Locally Advanced and Metastatic Pancreatic Cancer [TELOVAC]', 'orgStudyIdInfo': {'id': 'CDR0000528021'}, 'secondaryIdInfos': [{'id': 'CRUK-TELOVAC-V4'}, {'id': 'EUDRACT-2006-000461-10'}, {'id': 'EU-20683'}, {'id': 'ISRTCN43482138'}]}, 'armsInterventionsModule': {'interventions': [{'name': 'sargramostim', 'type': 'BIOLOGICAL'}, {'name': 'telomerase peptide vaccine GV1001', 'type': 'BIOLOGICAL'}, {'name': 'capecitabine', 'type': 'DRUG'}, {'name': 'gemcitabine hydrochloride', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'locations': [{'zip': 'EX31 4JB', 'city': 'Barnstaple', 'state': 'England', 'country': 'United Kingdom', 'facility': 'North Devon District Hospital', 'geoPoint': {'lat': 51.08022, 'lon': -4.05808}}, {'zip': 'RG24 9NA', 'city': 'Basingstoke', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Basingstoke and North Hampshire NHS Foundation Trust', 'geoPoint': {'lat': 51.26249, 'lon': -1.08708}}, {'zip': 'PE21 9QT', 'city': 'Boston', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Pilgrim Hospital', 'geoPoint': {'lat': 52.97633, 'lon': -0.02664}}, {'zip': 'BH7 7DW', 'city': 'Bournemouth', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Royal Bournemouth Hospital', 'geoPoint': {'lat': 50.72048, 'lon': -1.8795}}, {'zip': 'BN2 5BE', 'city': 'Brighton', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Sussex Cancer Centre at Royal Sussex County Hospital', 'geoPoint': {'lat': 50.82838, 'lon': -0.13947}}, {'zip': 'BS2 8ED', 'city': 'Bristol', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Bristol Haematology and Oncology Centre', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'zip': 'CB2 0QQ', 'city': 'Cambridge', 'state': 'England', 'country': 'United Kingdom', 'facility': "Addenbrooke's Hospital", 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'zip': 'DA2 8DA', 'city': 'Dartford Kent', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Darent Valley Hospital'}, {'zip': 'DT1 2JY', 'city': 'Dorchester', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Dorset County Hospital', 'geoPoint': {'lat': 50.71667, 'lon': -2.43333}}, {'zip': 'EX2 5DW', 'city': 'Exeter', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Royal Devon and Exeter Hospital', 'geoPoint': {'lat': 50.7236, 'lon': -3.52751}}, {'zip': 'GU2 7XX', 'city': 'Guildford', 'state': 'England', 'country': 'United Kingdom', 'facility': "St. Luke's Cancer Centre at Royal Surrey County Hospital", 'geoPoint': {'lat': 51.23536, 'lon': -0.57427}}, {'zip': 'HD3 3EA', 'city': 'Huddersfield, West Yorks', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Huddersfield Royal Infirmary', 'geoPoint': {'lat': 53.64904, 'lon': -1.78416}}, {'zip': 'IP4 5PD', 'city': 'Ipswich', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Ipswich Hospital', 'geoPoint': {'lat': 52.05917, 'lon': 1.15545}}, {'zip': 'LS9 7TF', 'city': 'Leeds', 'state': 'England', 'country': 'United Kingdom', 'facility': "Leeds Cancer Centre at St. James's University Hospital", 'geoPoint': {'lat': 53.79648, 'lon': -1.54785}}, {'zip': 'LE1 5WW', 'city': 'Leicester', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Leicester Royal Infirmary', 'geoPoint': {'lat': 52.6386, 'lon': -1.13169}}, {'zip': 'L7 8XP', 'city': 'Liverpool', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Royal Liverpool University Hospital', 'geoPoint': {'lat': 53.41058, 'lon': -2.97794}}, {'zip': 'EC1A 7BE', 'city': 'London', 'state': 'England', 'country': 'United Kingdom', 'facility': "Saint Bartholomew's Hospital", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SE5 9NU', 'city': 'London', 'state': 'England', 'country': 'United Kingdom', 'facility': "Cancer Research UK Clinical Groups at Guy's King's & St. Thomas' Hospitals", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SW17 0QT', 'city': 'London', 'state': 'England', 'country': 'United Kingdom', 'facility': "St. George's Hospital", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'SW3 6JJ', 'city': 'London', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Royal Marsden - London', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'M20 4BX', 'city': 'Manchester', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Christie Hospital', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'CH63 4JY', 'city': 'Merseyside', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Clatterbridge Centre for Oncology'}, {'zip': 'TS4 3BW', 'city': 'Middlesbrough', 'state': 'England', 'country': 'United Kingdom', 'facility': 'James Cook University Hospital', 'geoPoint': {'lat': 54.57623, 'lon': -1.23483}}, {'zip': 'NE4 6BE', 'city': 'Newcastle upon Tyne', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Northern Centre for Cancer Treatment at Newcastle General Hospital', 'geoPoint': {'lat': 54.97328, 'lon': -1.61396}}, {'zip': 'NR31 6LA', 'city': 'Norfolk', 'state': 'England', 'country': 'United Kingdom', 'facility': 'James Paget Hospital'}, {'zip': 'HA6 2RN', 'city': 'Northwood', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Mount Vernon Cancer Centre at Mount Vernon Hospital', 'geoPoint': {'lat': 51.61162, 'lon': -0.42454}}, {'zip': 'NR4 7UY', 'city': 'Norwich', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Norfolk and Norwich University Hospital', 'geoPoint': {'lat': 52.62783, 'lon': 1.29834}}, {'zip': 'NG5 1PB', 'city': 'Nottingham', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Nottingham City Hospital', 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}, {'zip': 'OX3 7LJ', 'city': 'Oxford', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Churchill Hospital', 'geoPoint': {'lat': 51.75222, 'lon': -1.25596}}, {'zip': 'PE3 6DA', 'city': 'Peterborough', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Peterborough Hospitals Trust', 'geoPoint': {'lat': 52.57364, 'lon': -0.24777}}, {'zip': 'BH15 2JB', 'city': 'Poole Dorset', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Dorset Cancer Centre'}, {'zip': 'PO3 6AD', 'city': 'Portsmouth Hants', 'state': 'England', 'country': 'United Kingdom', 'facility': "Portsmouth Oncology Centre at Saint Mary's Hospital"}, {'zip': 'TN37 7RD', 'city': 'Saint Leonards-on-Sea', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Conquest Hospital', 'geoPoint': {'lat': 50.85565, 'lon': 0.5452}}, {'zip': 'SP2 8BJ', 'city': 'Salisbury', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Salisbury District Hospital', 'geoPoint': {'lat': 51.06931, 'lon': -1.79569}}, {'zip': 'S10 2SJ', 'city': 'Sheffield', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Cancer Research Centre at Weston Park Hospital', 'geoPoint': {'lat': 53.38297, 'lon': -1.4659}}, {'zip': 'SL2 4HL', 'city': 'Slough, Berkshire', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Wexham Park Hospital', 'geoPoint': {'lat': 51.50949, 'lon': -0.59541}}, {'zip': 'SM2 5PT', 'city': 'Sutton', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Royal Marsden - Surrey', 'geoPoint': {'lat': 51.35, 'lon': -0.2}}, {'zip': 'TQ2 7AA', 'city': 'Torquay Devon', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Torbay Hospital'}, {'zip': 'TR1 3LJ', 'city': 'Truro, Cornwall', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Royal Cornwall Hospital', 'geoPoint': {'lat': 50.26526, 'lon': -5.05436}}, {'zip': 'BN11 2DH', 'city': 'Worthing', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Worthing Hospital', 'geoPoint': {'lat': 50.81795, 'lon': -0.37538}}, {'zip': 'BA21 4AT', 'city': 'Yeovil', 'state': 'England', 'country': 'United Kingdom', 'facility': 'Yeovil District Hospital', 'geoPoint': {'lat': 50.94159, 'lon': -2.63211}}, {'zip': 'AB25 2ZN', 'city': 'Aberdeen', 'state': 'Scotland', 'country': 'United Kingdom', 'facility': 'Aberdeen Royal Infirmary', 'geoPoint': {'lat': 57.14369, 'lon': -2.09814}}, {'zip': 'G11 6NT', 'city': 'Glasgow', 'state': 'Scotland', 'country': 'United Kingdom', 'facility': 'Beatson West of Scotland Cancer Centre', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'zip': 'LL 18 5UJ', 'city': 'Rhyl, Denbighshire', 'state': 'Wales', 'country': 'United Kingdom', 'facility': 'Glan Clwyd Hospital', 'geoPoint': {'lat': 53.31929, 'lon': -3.49228}}, {'zip': 'LL13 7TD', 'city': 'Wrexham', 'state': 'Wales', 'country': 'United Kingdom', 'facility': 'Wrexham Maelor Hospital', 'geoPoint': {'lat': 53.04664, 'lon': -2.99132}}], 'overallOfficials': [{'name': 'Gary W. Middleton', 'role': 'STUDY_CHAIR', 'affiliation': "St. Luke's Cancer Centre at Royal Surrey County Hospital"}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Royal Liverpool University Hospital', 'class': 'OTHER_GOV'}}}}